US stocks · Open buy, week 7
CRISPR Therapeutics gains 2.2% on a bounce off its 20-day average, ceiling just overhead
Our view last week
A week after a 9.4% rebound, CRISPR Therapeutics stock gives back 4.1% and the price action turns: buying stayed below 25% of volume in the weekly bar, and a bearish engulfing has formed on the daily chart. Price has stalled under the cluster of daily moving averages, in the 54.6 area. The weekly buy signal is still 1.3% in profit: a swing trading setup among US stocks to handle with discipline.
This week's summary
The bounce came where it had to: after touching its 20-day moving average in the 54 area, CRISPR Therapeutics stock rebounded 2% and closed the week up 2.2%, following last week's 4.1% drop. A ceiling sits right overhead, though: the 200-week average, in the 55.6 area, was touched and held. Money flow, negative for 6 weeks, also weighs on the technical analysis. The weekly buy signal is still 3.5% in profit: a swing trading setup to follow through the price action of the coming days.
IQS Phase
36
ordinary
Signal Strength
86
high · wide & volatile
Sizing
FULL
Ranking
#7 / 93
US stocks in progress
Trade P&L %
+3.51%
from signal to date, no stop loss
CRISPR Therapeutics (CRSP) weekly chart — EMA50 · MACD · VWAP
Weekly chart · EMA50 · MACD · VWAP · Source: TradingView
Rank position
ranks 7th among the 93 Longs already running for US stocks in our ranking, with a signal strength of 86 out of 100.
Sector context
SectorHealth Care
Benchmark ETFXLV
Sector regimein positive regime
Performanceweekly -2.65% · monthly -3.91%
CRSP belongs to the health care sector (reference ETF XLV). The sector is classified in positive regime according to our weekly reading.
restricted Platinum content